KRAS and cancer: Since a previous study has indicated that MDA-MB-231 cells are responsive to FSK treatment as well as mouse K-ras-transformed fibroblasts [15], we treated MDA-MB-231 cancer cells, grown in low glucose, with rotenone and FSK alone or in combination (schedule is shown in Figure 2(c)).